Novo Nordisk (NYSE: NVO) Eyes Large-Scale M&A Following Pfizer's (NYSE: PFE)Metsera Win - Semafor

• After losing a $10 billion bidding war for weight-loss startup Metsera to Pfizer, Novo Nordisk CFO Karsten Munk Knudsen signaled the company is hunting for even larger acquisitions to bolster its portfolio, according to reporting from Semafor.
• Management confirmed Novo has the balance sheet capacity for "bigger deals" than the Metsera valuation, prioritizing high-quality assets that align with its dominant position in the obesity and diabetes markets.